Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.11

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $61.11.

A number of research analysts have recently commented on the company. Piper Sandler upped their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research note on Monday, November 4th. HC Wainwright reiterated a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, Benchmark reaffirmed a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $39,988,802.96. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 60,000 shares of company stock worth $3,425,000. Corporate insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $434,000. M&T Bank Corp grew its position in Halozyme Therapeutics by 0.5% in the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company's stock valued at $6,367,000 after acquiring an additional 561 shares in the last quarter. Chiron Investment Management LLC grew its position in Halozyme Therapeutics by 23.6% in the 3rd quarter. Chiron Investment Management LLC now owns 23,502 shares of the biopharmaceutical company's stock valued at $1,345,000 after acquiring an additional 4,491 shares in the last quarter. Coldstream Capital Management Inc. grew its position in shares of Halozyme Therapeutics by 34.7% during the third quarter. Coldstream Capital Management Inc. now owns 9,251 shares of the biopharmaceutical company's stock worth $534,000 after buying an additional 2,384 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after buying an additional 30,901 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 7.2 %

HALO traded up $3.30 on Friday, hitting $49.00. The company had a trading volume of 4,549,681 shares, compared to its average volume of 2,110,864. The company has a market cap of $6.23 billion, a PE ratio of 16.23, a PEG ratio of 0.42 and a beta of 1.29. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The business's fifty day simple moving average is $54.58 and its 200 day simple moving average is $53.57.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.